Stock Price Quote

DR AGARWALS EYE HOSPITAL LTD.

NSE : NABSE : 526783ISIN CODE : INE934C01018Industry : Hospital & Healthcare ServicesHouse : Private
BSE2725.45-56.25 (-2.02 %)
PREV CLOSE ( ) 2781.70
OPEN PRICE ( ) 2762.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 904
TODAY'S LOW / HIGH ( )2715.00 2840.00
52 WK LOW / HIGH ( ) 8333031
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 22-04 1994
Management Info
Amar Agarwal - Chairman Amar Agarwal - Managing Director
Registered Office

Address 3rd Floor, Buhari Towers,No.4, Moores Road,Off. Greams Road, Near Asan Memorial School,
Chennai,
Tamil Nadu-600006

Phone 044-43787777 / 78

Email info@dragarwal.com

Website www.dragarwal.com

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE

NEWS

19Jun Dr.Agarwals Eye Hospital informs about
Dr.Agarwals Eye Hospital has informed that the share certificates held b..
19Jun Dr.Agarwals Eye Hospital informs about
Dr.Agarwals Eye Hospital has informed that the share certificates held b..
30Jan Dr. Agarwal's Eye Hospital informs abo
In pursuance of Regulation 39 (3) of SEBI (Listing Obligations and Discl..
06Jan Dr. Agarwal's Eye Hospital informs abo
In pursuance of Regulation 39(3) of SEBI (Listing Obligations and Disclo..
13Oct Dr.Agarwals Eye Hospital informs about
In pursuance of Regulation 39 (3) of SEBI (Listing Obligations and Discl..

Financials

in Millions
QTR Sep 23 ANNUAL 23
Net Profit125.9369.2
Gross Profit 166.5 494
Operating Profit 246.8764.5
Net Sales 832.72678.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Global Health (BSE)
peergroup  1004.45 (2.52%)
M.Cap ( in Cr)26962.19
Krishna Inst.Medi (BSE)
peergroup  1990.25 (0.77%)
M.Cap ( in Cr)15927.53
RainbowChildrenS Med (BSE)
peergroup  1121.75 (1.08%)
M.Cap ( in Cr)11385.95
Dr. Lal Pathlabs (BSE)
peergroup  2699.05 (0.34%)
M.Cap ( in Cr)22531.09
Thyrocare Tech. (BSE)
peergroup  585.80 (1.05%)
M.Cap ( in Cr)3101.97

Shareholding Pattern

PROMOTERS 71.9%
NON-INSTITUTION 27.82%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Dr Agarwals Eye Hospital Ltd.

Dr Agarwals Eye Hospital Ltd. was incorporated in the year 1994. Its today's share price is 2725.45. Its current market capitalisation stands at Rs 1280.96 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2678.9 Cr and Total Income of Rs.2699.4 Cr. The company's management includes Adil Agarwal, Lakshmi Subramanian, Balakrishnan Venkatraman, Sanjay Anand, Athiya Agarwal, Amar Agarwal, Amar Agarwal, Meenakshi Jayaraman.

It is listed on the BSE with a BSE Code of 526783 , NSE with an NSE Symbol of and ISIN of INE934C01018. It's Registered office is at 3rd Floor, Buhari Towers,No.4, Moores Road,Off. Greams Road, Near Asan Memorial SchoolChennai-600006, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, MK Dandekar & Co, MK Dandeker & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.